Transense Technologies plc

("Transense" or the "Company")

 Grant of share options

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement systems, announces that on 12 May 2026, the Company's remuneration committee (the "Remuneration Committee") approved the grant of 100,000 share options (the "Options") to acquire ordinary shares of 10 pence each in the Company ("Ordinary Shares") to Ryan Maughan, the Company's Managing Director.

In accordance with the Company's share scheme, the Options are subject to performance criteria and have an exercise price of 10 pence per share, being nominal value, and can be exercised after three years until the tenth anniversary of the grant. Two thirds of the Options are exercisable if the Company's share price reaches or exceeds 150 pence per share for ten consecutive trading days at any time, and no Options are exercisable unless this is achieved. The remaining third are exercisable, in full, if the share price reaches or exceeds 200 pence per share for ten consecutive trading days at any time. None of this tranche is exercisable if the share price has not reached 150 pence per share for ten consecutive trading days and a pro‐rata amount will be exercisable between these two share price targets. 

Following this grant, Ryan Maughan is now interested in a total of 450,000 share options in the Company.

205,000 additional Options have been granted to other employees on the same basis. Following these grants, the Company has a total of 1,895,000 options outstanding, representing approximately 11.53% of the Company's issued share capital.

The Company's remuneration policy approved by shareholders by an advisory vote at the Annual General Meeting in November 2024 permits overall headroom for the grant of share options of 15% of the issued share capital in any ten year period. 

For further information please visit https://www.transense.com or contact:

Notes to Editors:

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency, and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, automotive, and industrial machinery (including robotics), enabling improved efficiency and performance of their products. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied, Airbus and several other confidential Tier One automotive, aerospace and industrial machinery suppliers.

Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. Enabling accurate measurement and digital capture of safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software, and a growing list of international territory distribution partners.

In addition, Transense earns residual royalty income from Bridgestone iTrack - a tyre monitoring system for off-highway vehicles that was developed by Translogik. The associated sales, support and development infrastructure were sold to Bridgestone Corporation, the world's largest tyre producer, in June 2020, and the intellectual property was licensed exclusively to Bridgestone under a ten-year deal expiring in 2030.

Find out more at: https://www.transense.com/ 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them